Abbott Laboratories: PharmaVitae Profile

Table of Contents

ABOUT THIS PROFILE

PharmaVitae Explorer database Chapter structure Quarterly news update Company introduction Company sales Company financials Key products and competitors Data sourcing Analyst consensus

EXECUTIVE SUMMARY

• Key findings
• Prescription pharmaceutical sales and growth rate performance, 2002 - 14
• Financial performance, 2002 - 14
• Abbott: PharmaVitae forecasts at a glance
• Strategic insight
  • (Untitled sub-section)
  • Abbott can boast the number one share of the immunology and inflammation biologic space
  • Evolution of lipid management portfolio positions Abbott as a leader in the lucrative dyslipidemia market
• SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats

QUARTERLY NEWS UPDATE

• Product developments
• Deals and alliances
• M&A activity
• Company announcements
• Future product milestones

COMPANY INTRODUCTION

• Key findings
• Background
• Key corporate developments
• M&A history
  • Knoll Pharmaceuticals
  • Guidant' s vascular business
  • Kos Pharmaceuticals
  • Advanced Medical Optics
  • M&A strategy
• Current corporate structure

COMPANY SALES

• Key findings
• Prescription pharmaceutical sales and growth rate analysis, 2002 - 14
  • Historical analysis
  • Forecast analysis
• Product analysis
  • Product analysis, 2002 - 08
  • Product analysis, 2008 - 14
• Therapy area analysis
• Geographic analysis
• Launch/core/expiry analysis
  • Explanation of launch/core/expiry analysis
  • Launch analysis, 2008 - 14
  • Core analysis, 2008 - 14
  • Expiry analysis, 2008 - 14
• Molecule type analysis
• Externalization analysis

COMPANY FINANCIALS

• Key findings
• Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002 - 08
• Operating costs and profit analysis
  • Operating costs and profit analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2008 - 14
  • Operating costs and profit analysis, 2008 - 14

KEY PRODUCTS AND COMPETITORS

• Key findings
• Overview
• Immunology and inflammation
  • Humira
• Cardiovascular
  • Fenofibrate franchise (TriCor/TRILIPIX/Certriad)
  • Niaspan/Simcor
• Infectious diseases
  • Kaletra
• Respiratory
  • Flutiform
• Oncology
  • Lupron
• Central nervous system
  • Depakote

APPENDIX

• R&D pipeline
• References
• Abbreviations
• Exchange rates

TABLES

• Table: Abbott - PharmaVitae forecasts at a glance
• Table: Anti-TNF market overview
• Table: Overview of Abbott' s lipid management portfolio
• Table: Abbott key product developments, 2009
• Table: Abbott product deals and alliances, 2009
• Table: Abbott M&A activity, 2009
• Table: Abbott company announcements, 2009
• Table: Abbott future product milestones, 2009 - 11
• Table: Abbott product portfolio overview ($m), 2002 - 08
• Table: Abbott product portfolio overview ($m), 2008 - 14
• Table: Abbott prescription pharmaceutical sales by therapy area ($m), 2008 - 14
• Table: Abbott prescription pharmaceutical sales by geographic region ($m), 2008 - 14
• Table: Abbott launch portfolio overview ($m), 2008 - 14
• Table: Abbott core portfolio overview ($m), 2008 - 14
• Table: Abbott expiry portfolio overview ($m), 2008 - 14
• Table: Abbott prescription pharmaceutical sales by molecule type ($m), 2008 - 14
• Table: Abbott prescription pharmaceutical sales by source ($m), 2008 - 14
• Table: Total Abbott sales by business unit ($m), 2002 - 08
• Table: Abbott operating revenue/cost analysis ($m), 2002 - 08
• Table: Abbott operating cost ratio analysis (% of total revenues), 2002 - 08
• Table: Abbott operating cost ratio analysis (% of total revenues), 2008 - 14
• Table: Abbott operating revenue/cost analysis ($m), 2008 - 14
• Table: Key products overview
• Table: Humira: overview
• Table: Humira: sales forecast ($m), 2008 - 14
• Table: Anti-TNF market overview
• Table: TriCor/TRILIPIX: overview
• Table: Certriad: overview
• Table: TriCor/TRILIPIX: sales forecast ($m), 2008 - 14
• Table: Certriad: sales forecast ($m), 2008 - 14
• Table: Niaspan: overview
• Table: Simcor: overview
• Table: Niaspan: sales forecast ($m), 2008 - 14
• Table: Simcor: sales forecast ($m), 2008 - 14
• Table: Kaletra: overview
• Table: Kaletra: sales forecast ($m), 2008 - 14
• Table: Top six anti-HIV treatments, global sales ($m) 2008
• Table: Flutiform: overview
• Table: Flutiform: sales forecast ($m), 2008 - 14
• Table: Lupron: overview
• Table: Lupron: sales forecast ($m), 2008 - 14
• Table: Depakote: overview
• Table: Depakote: sales forecast ($m), 2008 - 14
• Table: Top antiepileptic therapeutics, sales ($m) 2002 - 08
• Table: Abbott' s R&D pipeline (Phase I - registration)
• Table: Exchange rates, 2009

FIGURES

• Figure: The PharmaVitae Explorer
• Figure: Abbott prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: Abbott' s financial performance ($m), 2002 - 14
• Figure: I&I biologic sales by company (% total market), 2002 - 14
• Figure: Sales of Abbott' s lipid management portfolio ($m), 2002 - 14
• Figure: Abbott SWOT analysis
• Figure: Current corporate structure
• Figure: Abbott prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: Key product sales ($m), 2002 - 14
• Figure: Abbott key sales growth drivers and resistors ($m), 2002 - 08
• Figure: Abbott key sales growth drivers and resistors ($m), 2008 - 14
• Figure: Abbott prescription pharmaceutical sales by therapy area ($m), 2002 - 14
• Figure: Abbott prescription pharmaceutical sales by geographic region ($m), 2002 - 14
• Figure: Abbott launch/core/expiry configuration ($m), 2008 - 14
• Figure: Abbott prescription pharmaceutical sales by molecule type ($m), 2002 - 14
• Figure: Abbott prescription pharmaceutical sales by source ($m), 2002 - 14
• Figure: Abbott operating revenue/cost analysis ($m), 2002 - 14